Rheumatoid Arthritis

What it is

Rheumatoid arthritis is a chronic autoimmune disease that inflames joints; WHO estimated 18 million people were living with it in 2019. RA most often affects the small joints of the hands, wrists, and feet in a symmetric pattern, but it is not only a joint disease. It can also involve the lungs, heart, eyes, skin, blood vessels, and nerves. The key clinical point is that early treatment matters: ongoing inflammation can damage cartilage and bone, causing erosions, deformity, disability, and reduced quality of life.

RA happens when the immune system mistakenly targets the synovium, the lining around joints. This causes pain, swelling, warmth, and morning stiffness that often lasts longer than 30 to 60 minutes. Symptoms may begin gradually over weeks to months, and fatigue, low-grade fever, and malaise are common. Women are affected more often than men, and onset is common in midlife or later adulthood.

Common features include:

Feature	Typical pattern in RA
Joint involvement	Usually small joints first: fingers, wrists, feet
Symmetry	Often affects both sides of the body
Stiffness	Often worse in the morning or after rest
Course	Chronic, with flares and quieter periods
Beyond joints	Can affect lungs, heart, eyes, skin, and blood

In India, RA is routinely managed by rheumatologists and internal medicine specialists, and delayed diagnosis remains a practical issue because early symptoms can be mistaken for general body pain, osteoarthritis, or post-viral joint pain.

How it works

RA is driven by immune dysregulation in genetically susceptible people, likely triggered or amplified by environmental factors. Smoking is one of the best-established risk factors, and obesity and air pollution have also been linked with higher risk. The immune system activates inflammatory cells and signaling molecules in the synovium, which thickens and becomes invasive. Over time, this inflamed tissue damages cartilage, erodes bone, and weakens surrounding tendons and ligaments.

Two antibodies are especially important in RA:

1. Rheumatoid factor (RF)
2. Anti-citrullinated protein antibodies (ACPA, often measured as anti-CCP)

These antibodies are not present in every patient, but when anti-CCP is positive, it can support the diagnosis and may be associated with more erosive disease. Not all RA is seropositive, however. Some people have classic inflammatory arthritis with negative RF and anti-CCP, called seronegative RA.

Inflammation in RA is systemic, which helps explain why untreated disease is linked with higher cardiovascular risk, anemia of chronic inflammation, osteoporosis, and fatigue.

Diagnosis / how it's measured

RA is diagnosed from the overall clinical picture, not from a single test. Doctors consider symptoms, joint examination, blood tests, and imaging. Early RA can be difficult to confirm because symptoms overlap with viral arthritis, lupus, psoriatic arthritis, gout, and osteoarthritis.

Typical parts of evaluation include:

Test or assessment	What it helps show
History and joint exam	Pattern of pain, swelling, stiffness, symmetry
RF	Supportive but not specific for RA
Anti-CCP / ACPA	More specific than RF for RA
ESR and CRP	Level of inflammation
CBC	Anemia or other blood abnormalities
X-ray, ultrasound, or MRI	Erosions, synovitis, joint damage

Doctors often use the 2010 ACR/EULAR classification criteria to support diagnosis in people with inflammatory synovitis. The score incorporates number and site of joints involved, serology, inflammatory markers, and symptom duration. In practice, persistent swelling in small joints plus prolonged morning stiffness should prompt evaluation, especially if symptoms last more than 6 weeks.

Evidence and uses

The main goal of treatment is remission or low disease activity as early as possible. Modern RA care uses a treat-to-target approach, meaning treatment is adjusted based on symptoms, joint counts, blood markers, and function until inflammation is well controlled.

Main treatment categories include:

Treatment type	Examples	Role
Conventional DMARDs	Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide	First-line disease control
Biologic DMARDs	TNF inhibitors, abatacept, rituximab, IL-6 inhibitors	For inadequate response to conventional drugs
Targeted synthetic DMARDs	JAK inhibitors	Oral options for selected patients
NSAIDs	Ibuprofen, naproxen	Symptom relief, not disease control
Corticosteroids	Prednisolone	Short-term bridge therapy or flare control

Methotrexate is commonly the anchor drug unless contraindicated. NSAIDs and steroids can reduce pain and stiffness, but they do not prevent long-term joint damage on their own. Physical therapy, hand exercises, joint protection strategies, smoking cessation, weight management, and rehabilitation are also important.

Evidence strongly supports early DMARD treatment to reduce erosions, disability, and extra-articular complications. Surgery, including synovectomy or joint replacement, may help when there is severe structural damage despite medical treatment.

Some patients ask about dietary changes, supplements, yoga, or traditional systems of medicine. Exercise and rehabilitation have supportive evidence for function and pain. Diet quality matters for overall health, but no single food cures RA. Traditional and herbal approaches may be used by some patients in India, but evidence for disease control is generally limited compared with DMARDs, and they should not replace proven treatment.

When to see a clinician

See a clinician promptly if you have joint pain with swelling and morning stiffness lasting more than a few weeks, especially if the same joints on both sides are affected. Early referral to a rheumatologist is important because joint damage can begin early in the disease course.

Urgent review is needed if RA symptoms are accompanied by chest pain, shortness of breath, severe eye pain or redness, marked weakness, fever, or signs of infection. People already taking RA medicines should seek advice quickly for cough, fever, painful urination, shingles, or unusual bruising because some treatments suppress the immune system.

Limitations and open questions

RA is well studied, but important uncertainties remain. The exact trigger is still not known, and the disease likely reflects a mix of genes, smoking, mucosal immune changes, hormones, and environmental exposures. Not every patient has positive antibodies, and disease course varies widely.

Treatment has improved outcomes substantially, but some people do not respond fully or lose response over time. Researchers are studying how to predict which therapy will work best for a given patient, how to prevent RA before symptoms start in high-risk people, and how to reduce long-term cardiovascular and lung complications. Evidence for complementary therapies in humans is mixed or limited, so they should be viewed as adjuncts, not substitutes for standard care.